UPCC 12023: Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation
Brief description of study
Please refer to Protocol Section 2 (Study Hypothesis/Objectives). Please refer to Protocol Section 3.5 (Primary Endpoints). Please refer to Protocol Section 3.6 (Secondary Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
09 Mar 2024.
Study ID: 854758
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
